Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody.
Int J Hematol
; 115(1): 7-10, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1604920
ABSTRACT
We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Linfoma de Células B
/
Anticuerpos Monoclonales Humanizados
/
COVID-19
/
Vacuna BNT162
Tópicos:
Covid persistente
/
Vacunas
/
Variantes
Límite:
Anciano
/
Femenino
/
Humanos
/
Masculino
/
Middle aged
Idioma:
Inglés
Revista:
Int J Hematol
Asunto de la revista:
Hematología
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
S12185-021-03247-y
Similares
MEDLINE
...
LILACS
LIS